Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome

Withdrawn before enrolling · Phase 3

Conditions studied: Marfan Syndrome

In brief

Transforming Growth Factor Beta (TGF-β) is a protein that controls proliferation, cellular differentiation, and other functions in most cells. TGF-β levels play a major role in the pathogenesis of Marfan syndrome, a disease characterized by disproportionate height, long extremities, lens dislocation in the eyes and heart complications such as mitral valve prolapse and aortic enlargement increasing the likelihood of aortic dissection. While the underlying defect in Marfan syndrome is faulty synthesis of the glycoprotein fibrillin I, normally an important component of elastic fibers it has been shown that the Marfan syndrome phenotype can be relieved by addition of a TGF-β antagonist in affected mice.

Key facts

Study ID

NCT01361087

Run by

Ann & Robert H Lurie Children's Hospital of Chicago

People needed

0

Starts

2011-04-01

Last updated by the study team

2016-02-05

Who can join

Age: 1 and older, up to 24. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individual with Marfan syndrome consented in to the Main Atenolol Vs. Losartan NIH study.

You may not qualify if…

• Subjects in the main PHN Marfan trial who have not achieved the maintenance drug dosing or who have stopped taking study drug.

Where it is running

• Children's Memorial Hospital Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.